UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

Science (American Association for the Advancement of Science), 2019-11, Vol.366 (6468), p.1013-1021

2019

Volltextzugriff (PDF)

Hunger Pains: Stimulating the Appetite of the Immune System for Cancer

Cancer cell, 2016-07, Vol.30 (1), p.13-15

2016

Volltextzugriff (PDF)

The Receptor for Advanced Glycation End Products Is a Central Mediator of Asthma Pathogenesis

The American journal of pathology, 2012-10, Vol.181 (4), p.1215-1225

2012

Volltextzugriff (PDF)

A Role for the Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis

The American journal of pathology, 2008-03, Vol.172 (3), p.583-591

2008

Volltextzugriff (PDF)

Oxidative Stress Alters Syndecan-1 Distribution in Lungs with Pulmonary Fibrosis

The Journal of biological chemistry, 2009-02, Vol.284 (6), p.3537-3545

2009

Volltextzugriff (PDF)

Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice

PloS one, 2011-05, Vol.6 (5), p.e20132-e20132

2011

Volltextzugriff (PDF)

Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells

The Journal of clinical investigation, 2020-07, Vol.130 (7), p.3865-3884

2020

Volltextzugriff (PDF)

Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products

PloS one, 2014-03, Vol.9 (3), p.e88259

2014

Volltextzugriff (PDF)

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Clinical cancer research, 2020-02, Vol.26 (4), p.846-854

2020

Volltextzugriff (PDF)

The role of the receptor for advanced glycation end-products in a murine model of silicosis

PloS one, 2010-03, Vol.5 (3), p.e9604

2010

Volltextzugriff (PDF)

A novel method for accurate collagen and biochemical assessment of pulmonary tissue utilizing one animal

International journal of clinical and experimental pathology, 2011-04, Vol.4 (4), p.349-355

2011

Volltextzugriff (PDF)

Large scale isolation and purification of soluble RAGE from lung tissue

Protein expression and purification, 2008-09, Vol.61 (1), p.99-101

2008

Volltextzugriff (PDF)

Abstract 4364: Adenosine A2a receptor blockade as a means of enhancing immune checkpoint inhibition and adoptive T-cell therapy

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4364-4364

2016

Volltextzugriff (PDF)

Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis

International journal of clinical and experimental pathology, 2011-03, Vol.4 (3), p.241-254

2011

Volltextzugriff (PDF)

Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3099-3099

2023

Volltextzugriff (PDF)

Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3084-3084

2022

Volltextzugriff (PDF)

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3006-3006

2021

Volltextzugriff (PDF)

Abstract 573: Metabolism as checkpoint: Induction of anti-tumor immune response with the novel glutamine antagonist JHU-083

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.573-573

2017

Volltextzugriff (PDF)

Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9041-9041

2018

Volltextzugriff (PDF)

Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3028-3028

2018

Volltextzugriff (PDF)

Oxidative Stress Alters Syndecan-1 Distribution in Lungs with Pulmonary FibrosisS

The Journal of biological chemistry, 2009-02, Vol.284 (6), p.3537-3545

2009

Volltextzugriff (PDF)

Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4123-4123

2018

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Animals
(11)
Life Sciences & Biomedicine
(9)
Mice
(9)
Male
(8)
Mice, Inbred C57bl
(8)
Pathology
(7)
Humans
(6)
Mice, Knockout
(6)
Receptor For Advanced Glycation End Products
(6)
Lung - Metabolism
(5)
Receptors, Immunologic - Metabolism
(5)
Inflammation
(4)
Multidisciplinary Sciences
(4)
Oncology
(4)
Receptors, Immunologic - Genetics
(4)
Rodents
(4)
Science & Technology - Other Topics
(4)
Advanced Glycosylation End Products
(3)
Animal Models
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

Hunger Pains: Stimulating the Appetite of the Immune System for Cancer

The Receptor for Advanced Glycation End Products Is a Central Mediator of Asthma Pathogenesis

A Role for the Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis

Oxidative Stress Alters Syndecan-1 Distribution in Lungs with Pulmonary Fibrosis

Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice

Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells

Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

The role of the receptor for advanced glycation end-products in a murine model of silicosis

A novel method for accurate collagen and biochemical assessment of pulmonary tissue utilizing one animal

Large scale isolation and purification of soluble RAGE from lung tissue

Abstract 4364: Adenosine A2a receptor blockade as a means of enhancing immune checkpoint inhibition and adoptive T-cell therapy

Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis

Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors

Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers

Abstract 573: Metabolism as checkpoint: Induction of anti-tumor immune response with the novel glutamine antagonist JHU-083

Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients

Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC

Oxidative Stress Alters Syndecan-1 Distribution in Lungs with Pulmonary FibrosisS

Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc)

Suchergebnisse filtern